公开(公告)号：WO2007128109A1

公开(公告)日：2007-11-15

申请号：PCT/CA2007/000757

申请日：2007-05-04

Applicant: UNIVERSITY HEALTH NETWORK ,  FERREIRA, Cátia, Sofia, Matos ,  GARIÉPY, Jean

Inventor： FERREIRA, Cátia, Sofia, Matos ,  GARIÉPY, Jean

IPC: C07H21/04 ,  A61K31/711 ,  A61P35/00 ,  G01N33/574

CPC classification number: G01N33/5308 ,  A61K31/711 ,  G01N33/57469 ,  G01N2333/4725

Abstract: Novel oligonucleotides, termed aptamers, that bind to GalNac of the Tn antigen. In particular, aptamers that recognize the Tn antigen on a cancer cell or underglycosylated protein are disclosed. Uses of the aptamers to detect, monitor or treat cancer are also described.

Abstract translation: 称为适体的新型寡核苷酸，其结合Tn抗原的GalNac。 特别地，公开了识别癌细胞或糖基化蛋白质上的Tn抗原的适体。 还描述了适配体检测，监测或治疗癌症的用途。

公开(公告)号：WO2007098607A1

公开(公告)日：2007-09-07

申请号：PCT/CA2007/000346

申请日：2007-03-05

Applicant: AMORFIX LIFE SCIENCES LTD. ,  UNIVERSITY HEALTH NETWORK ,  CASHMAN, Neil, R. ,  CHAKRABARTTY, Avijit ,  RAKHIT, Rishi ,  OSTERMAN, Joachim, Bernhard

Inventor： CASHMAN, Neil, R. ,  CHAKRABARTTY, Avijit ,  RAKHIT, Rishi ,  OSTERMAN, Joachim, Bernhard

IPC: C12N15/53 ,  A61K31/7088 ,  A61K38/44 ,  A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  A61P25/28 ,  C07K16/40 ,  C12N5/12 ,  C12N9/02 ,  G01N33/573

CPC classification number: C07K16/40 ,  A01K2267/0312 ,  A01K2267/0318 ,  A61K31/7088 ,  A61K31/713 ,  A61K39/0005 ,  A61K39/0007 ,  A61K48/005 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/575 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/0089 ,  G01N33/573 ,  G01N33/6896 ,  G01N2333/90283 ,  G01N2800/2828

Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1. In addition, the invention includes methods of diagnosing Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis in a subject. Also, the invention provides methods of identifying substances for the treatment or prevention of Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis and kits using the binding proteins of the invention.

Abstract translation: 本发明提供了在需要治疗的受试者中治疗由错误折叠形式的超氧化物歧化酶（SOD）介导的医学病症，疾病或病症的方法。 所述方法任选包括向受试者施用包含药学上可接受的载体和选自（1）选择性结合SOD的错误折叠形式的外源性抗体或其片段的组合物，和/或（2）引起生产的免疫原 选择性结合SOD的错误折叠形式的内源性抗体，和/或（3）编码（1）或（2）的核酸序列。 在某些实施方案中，本发明提供了使用肌萎缩性疾病特异性表位治疗疾病如阿尔茨海默病，帕金森病或肌萎缩性侧索硬化的方法，以及包括这些表位的组合物。 本发明还提供结合单体或错折叠的SOD1，而不是在天然同二聚体SOD1的分子表面上的抗体。 此外，本发明包括在受试者中诊断阿尔茨海默病，帕金森病或肌萎缩性侧索硬化的方法。 此外，本发明提供了鉴定用于治疗或预防阿尔茨海默病，帕金森病或肌萎缩性侧索硬化的物质以及使用本发明的结合蛋白的试剂盒的方法。

公开(公告)号：WO2007056854A1

公开(公告)日：2007-05-24

申请号：PCT/CA2006/001870

申请日：2006-11-20

Applicant: UNIVERSITY HEALTH NETWORK ,  ZHANG, Li ,  HAN, Mei ,  DOKOUHAKI, Pouneh

Inventor： ZHANG, Li ,  HAN, Mei ,  DOKOUHAKI, Pouneh

IPC: C12N5/08 ,  A61K35/12 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  C12N5/02 ,  C12N5/06

CPC classification number: A61K35/17 ,  C12N5/0636 ,  C12N2501/23 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/515

Abstract: A method of expanding double negative T cells in culture is described. The method comprises (a) providing a starting sample comprising DN T cells or precursors thereof; (b) substantially depleting CD8 + and CD4 + T cells from the starting sample; (c) culturing the sample from step (b) with an immobilized T cell mitogen in a culture medium comprising an agent that can stimulate DN T cell growth; (d) washing the cells obtained in step (c) and resuspending in a culture medium comprising the agent without the T cell mitogen; and (e) washing the cells obtained in step (d) and resuspending in a culture medium comprising the agent and a soluble T cell mitogen. The DN T cells obtained by the method are useful in a variety of applications including the treatment of cancer, infectious diseases, graft versus host disease and autoimmune disease.

Abstract translation: 描述了在培养中扩增双重负T细胞的方法。 该方法包括（a）提供包含DN T细胞或其前体的起始样品; （b）来自起始样品的基本上消耗CD8 +和/或CD4 + T细胞; （c）在包含可刺激DN T细胞生长的试剂的培养基中培养来自步骤（b）的样品与固定的T细胞丝裂原; （d）洗涤步骤（c）中获得的细胞，并重新悬浮在包含没有T细胞丝裂原的试剂的培养基中; 和（e）洗涤步骤（d）中获得的细胞，并重新悬浮于包含该试剂和可溶性T细胞丝裂原的培养基中。 通过该方法获得的DN T细胞可用于各种应用，包括治疗癌症，感染性疾病，移植物抗宿主病和自身免疫性疾病。

公开(公告)号：WO2006079216A1

公开(公告)日：2006-08-03

申请号：PCT/CA2006/000114

申请日：2006-01-30

Applicant: BC CANCER AGENCY ,  UNIVERSITY HEALTH NETWORK ,  WASAN, Ellen ,  BALLY, Marcel ,  COGSWELL, Sebastian ,  BERGER, Stuart

Inventor： WASAN, Ellen ,  BALLY, Marcel ,  COGSWELL, Sebastian ,  BERGER, Stuart

IPC: A61K31/4174 ,  A61P35/00 ,  A61P31/10 ,  A61K9/127 ,  A61K47/48

CPC classification number: A61K9/1271 ,  A61K9/1278 ,  A61K31/4174

Abstract: The invention provides methods and compositions for loading an agent, such as econazole, onto a liposome for parental delivery. The loading of the agent into a liposome comprises combining the agent with a micelle-forming compound to form a micelle including the agent, where the agent is releasable from the micelle-forming compound, and adding the micelle to the liposome, where the micelle combines with the liposome such that the agent is loaded into the liposome to form a loaded liposome. The methods are suitable for the loading of poorly soluble agents onto liposome.

Abstract translation: 本发明提供了用于将药剂（例如益康唑）加载到用于亲代递送的脂质体上的方法和组合物。 将试剂加载到脂质体中包括将试剂与胶束形成化合物组合以形成包含试剂的胶束，其中试剂可从胶束形成化合物释放，并将胶束加入脂质体中，其中胶束结合 与脂质体一起使得试剂加载到脂质体中以形成负载的脂质体。 该方法适用于将难溶性物质加载到脂质体上。

公开(公告)号：WO2006026109A1

公开(公告)日：2006-03-09

申请号：PCT/US2005/028563

申请日：2005-08-12

Applicant: BECKMAN, COULTER, INC. ,  UNIVERSITY HEALTH NETWORK

Inventor： CHOW, Sue ,  HEDLEY, David ,  SHANKEY, T., Vincent ,  GROM, Patricia

IPC: G01N33/53

CPC classification number: G01N33/80 ,  Y10T436/107497 ,  Y10T436/108331 ,  Y10T436/25 ,  Y10T436/25125 ,  Y10T436/2525 ,  Y10T436/25375

Abstract: This invention is directed to a method for preparation of a biological sample for measurement of protein epitopes that allows for the preservation of intracellular protein epitopes and detection of signal transduction pathways based on the ability to capture transient activation states of the epitopes. The method provided by the invention allows for the rapid fixation of biological samples containing red food cells, to ensure that epitopes of signal transduction molecules and other intracellular protein epitopes are preserved in the active state. The method of the invention further allows for lysis of red blood cells, thereby making it a useful method for cytometric analysis of biological samples, including, for example, whole blood, bone marrow aspirates, peritoneal fluids, and other red blood cell containing samples. The invention also provides a method to recover or "unmask" epitopes on intracellular antigens that have been made inaccessible by the cross linking fixative necessary to fix the sample. Significantly, the methods of the invention allow preservation and analysis of phospho-epitope levels in biological samples taken directly from patients to determine disease-specific characteristics.

Abstract translation: 本发明涉及一种用于制备用于测量蛋白质表位的生物样品的方法，其允许基于捕获表位的瞬时激活状态的能力来保留细胞内蛋白质表位和检测信号转导途径。 本发明提供的方法允许快速固定含有红色食物细胞的生物样品，以确保信号转导分子和其他细胞内蛋白质表位的表位保持在活性状态。 本发明的方法还允许红细胞溶解，从而使其成为生物样品的细胞分析的有用方法，包括例如全血，骨髓抽吸物，腹膜液和其它含红细胞的样品。 本发明还提供了一种在细胞内抗原上恢复或“揭开”表位的方法，这些表位已经被固定样品所必需的交联固定剂制成。 显着地，本发明的方法允许保存和分析直接从患者获取的生物样品中的磷酸化表位水平，以确定疾病特异性特征。

公开(公告)号：WO2005039479A3

公开(公告)日：2005-05-06

申请号：PCT/CA2004/001857

申请日：2004-10-22

Applicant: UNIVERSITY HEALTH NETWORK ,  BURCH, Shane ,  WILSON, Brian, C. ,  BISLAND, Stuart, K.

Inventor： BURCH, Shane ,  WILSON, Brian, C. ,  BISLAND, Stuart, K.

IPC: A61B17/86 ,  A61B18/22 ,  A61N5/06

Abstract: Photodynamic therapy (PDT) is used in the case of bone. A photosensitizing drug is administered to a mammal. A bone insertion member is secured into bone. A fiber optic cable sheath extends from within the bone insertion member and is accessible. A fiber optic cable is inserted in the fiber optic cable sheath to deliver light to the bone. A locking member is then attached to the insertion member. Non-thermal light at a specific wavelength is then delivered to activate the drug. The insertion member and the fiber optic cable sheath may remain inside the mammal for further photodynamic therapy.

公开(公告)号：WO2003061587A2

公开(公告)日：2003-07-31

申请号：PCT/US2003/001726

申请日：2003-01-21

Applicant: GENZYME CORPORATION ,  UNIVERSITY HEALTH NETWORK ,  KESHAVJEE, Shaf ,  ST. GEORGE, Judith, A. ,  LIU, Mingyao

Inventor： KESHAVJEE, Shaf ,  ST. GEORGE, Judith, A. ,  LIU, Mingyao

IPC: A61K

CPC classification number: C07K14/71 ,  A61K31/00 ,  A61K31/194 ,  A61K31/7004 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/495 ,  C12N2799/022

Abstract: Effective use of a TGF-β antagonist to treat or to prevent loss of transplant function is described herein. Use of a TGF-β antagonist is demonstrated to effectively prevent loss of organ function in a host due to chronic rejection in which TGF-β-mediated fibroproliferation is a characteristic. Expression in situ of a TGF-β antagonist in the form of a recombinant receptor, i.e., TGF-β type III receptor (TGFBIIIR) showed prevention of bronchiolitis obliterans in comparison to untreated controls in a rat lung transplant model. This provides an effective method for preventing or inhibiting chronic rejection of transplant organs such as lung, kidney, liver and hear in vertebrate hosts including human hosts.

Abstract translation: 有效利用TGF- 本文描述了治疗或预防移植功能丧失的拮抗剂。 使用TGF- 拮抗剂被证明能有效地防止由于慢性排斥反应导致宿主中器官功能的丧失，其中TGF-βB介导的纤维增生是一个特征。 TGF-βb原位表达 拮抗剂，其为重组受体的形式，即TGF- III型受体（TGFBIIIR）显示与大鼠肺移植模型中的未处理对照相比，预防闭塞性细支气管炎。 这提供了用于预防或抑制移植器官如肺，肾，肝脏的慢性排斥并在包括人宿主在内的脊椎动物宿主中听到的有效方法。

公开(公告)号：WO2003045415A2

公开(公告)日：2003-06-05

申请号：PCT/CA2002/001783

申请日：2002-11-26

Applicant: UNIVERSITY HEALTH NETWORK ,  GARIEPY, Jean

Inventor： GARIEPY, Jean

IPC: A61K38/00

CPC classification number: B82Y30/00 ,  A61K47/64 ,  A61K48/00 ,  B82Y5/00 ,  C12N15/87

Abstract: Novel delivery vehicles comprising peptide based domains that can self-assemble into multivalent assemblies are described. The multivalent assemblies are preferably tetrameric assemblies such as h p53 tet . The peptide domain is preferably fused to a signal molecule such as a polycationic molecule. The vehicles are useful in delivering a wide range of agents to a cell including peptides, vaccines, cytotoxic molecules, plasmids, genes, drugs and diagnostic probes or agents.

Abstract translation: 描述了包含能够自组装成多价组件的基于肽的结构域的新型递送载体。 多价组件优选为四聚体组件，例如hp53。 肽结构域优选与信号分子如聚阳离子分子融合。 载体可用于将多种试剂递送至包括肽，疫苗，细胞毒性分子，质粒，基因，药物和诊断探针或试剂的细胞。

公开(公告)号：WO2003038062A2

公开(公告)日：2003-05-08

申请号：PCT/US2002/035240

申请日：2002-10-31

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ,  UNIVERSITY HEALTH NETWORK ,  FOWLER, Daniel ,  JUNG, Unsu ,  MEDIN, Jeffrey, A. ,  GRESS, Ronald, E. ,  ERDMANN, Andreas ,  LEVINE, Bruce ,  JUNE, Carl

Inventor： FOWLER, Daniel ,  JUNG, Unsu ,  MEDIN, Jeffrey, A. ,  GRESS, Ronald, E. ,  ERDMANN, Andreas ,  LEVINE, Bruce ,  JUNE, Carl

IPC: C12N

CPC classification number: C12N5/0648 ,  A01K67/0271 ,  A61K39/001 ,  A61K2035/122 ,  A61K2035/124 ,  C12N5/0636 ,  C12N2500/32 ,  C12N2501/23 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2510/00 ,  C12N2799/021

Abstract: A method is provided for producing a population of CD8 + Tc1 and/or Tc2 lymphocytes ex vivo . The method includes stimulating a population of T cells obtained from a subject by contacting the population with an anti-CD3 monoclonal antibody and an antibody that specifically binds to a T cell costimulatory molecule in the presence of a Tc1 or Tc2 supportive environment to form a stimulated population of T cells. The stimulated population of CD8 + T cells is allowed to proliferate in a Tc1 or Tc2 supportive environment. Purified populations of Tc1 and Tc2 cells are disclosed herein, as are methods for their use.

Abstract translation: 提供了用于离体生产CD8 + Tc1和/或Tc2淋巴细胞群的方法。 该方法包括通过使人群与抗CD3单克隆抗体和在Tc1或Tc2支持环境的存在下特异性结合T细胞共刺激分子的抗体接触，从而刺激从受试者获得的T细胞群体，以形成受刺激的 T细胞群体 CD8 + T细胞的受刺激群体允许在Tc1或Tc2支持环境中增殖。 本文公开了Tc1和Tc2细胞的纯化群体，以及它们的使用方法。

公开(公告)号：WO2023082022A1

公开(公告)日：2023-05-19

申请号：PCT/CA2022/051680

申请日：2022-11-14

Applicant: UNIVERSITY HEALTH NETWORK ,  CAMPO, David R. ,  URBANOWICZ, Richard A. ,  ABOUHAIDAR, Mounir G. ,  THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO ,  UNIVERSITY OF LIVERPOOL ,  CENTERS FOR DISEASE CONTROL AND PREVENTION

Inventor： MOSA, Alexander I. ,  FELD, Jordan J.

IPC: C07K14/18 ,  A61K39/29 ,  A61K39/385 ,  A61P31/14 ,  C07K14/435 ,  C07K19/00 ,  C12N15/40 ,  C12N15/62 ,  C12N15/85 ,  G16B20/20 ,  G16B30/00

Abstract: There is described herein polyvalent HCV vaccines, preferably comprising SEQ ID Nos. 1-5. There is also described herein methods of designing polyvalent vaccines.